高级检索
当前位置: 首页 > 详情页

Promoter methylation of BRMS1 correlates with smoking history and poor survival in non-small cell lung cancer patients.

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Center for Human Molecular Biology & Genetics, Institute of Laboratory Medicine, The Key Laboratory for Human Disease Gene Study of Sichuan Province, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, PR China [2]Department of Pathology, West China Second Hospital of Sichuan University, Chengdu, Sichuan, PR China [3]Department of Thoracic Surgery, Chengdu Army General Hospital, PR China [4]Laboratory of Early Developmental and Injuries, West China Institute of Woman and Children’s Health, West China Second University Hospital, Sichuan University, Chengdu, PR China [5]Key Laboratory of Birth Defects, Obstetric & Gynecologic and Pediatric Diseases (Sichuan University), Ministry of Education, PR China
出处:
ISSN:

关键词: Breast cancer metastasis suppressor 1 Non-small cell lung cancer DNA methylation Smoking history Survival time Prognosis

摘要:
To investigate whether methylation of BRMS1 is associated with clinical outcomes in patients with NSCLC. Methylation status of BRMS1 was examined in 325 NSCLC patients who were treated with surgery. We analyzed associations between the methylation of BRMS1 genes separately and available epidemiologic and clinical information including smoking status, gender, age, and histological type, or the stage of the tumor. In the cohort of 325 NSCLC cases, 152 samples were identified as methylated (46.77%). Promoter methylation of BRMS1 was present only in 6 specimens (8.42%) in adjacent non-cancerous tissues (P=2.257 × 10(-14)). Patient smoking history had a positive correlation with methylation rate of BRMS1 (OR=2.508, 95%CI(1.516, 4.151)). Compared with unmethylated group, methylated group showed the lower level of BRMS1 mRNA (P=0.013). And patients with a high level of BRMS1 mRNA expression had significantly better overall survival than those with low expression (P=0.002). Multivariate Cox proportional hazard regression analysis also showed that promoter methylation of BRMS1 was significantly unfavorable prognostic factors (hazard ratio, 1.912; 95% CI, and 1.341-2.726). These results provide clinical evidence to support the notion that BRMS1 is a NSCLC metastasis suppressor gene. Measuring methylation status of BRMS1 promotor is a useful marker for identifying NSCLC patients with worse disease-free survival. Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2011]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学 3 区 呼吸系统
最新[2023]版:
大类 | 2 区 医学
小类 | 3 区 肿瘤学 3 区 呼吸系统
JCR分区:
出版当年[2011]版:
Q1 RESPIRATORY SYSTEM Q2 ONCOLOGY
最新[2023]版:
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子: 最新[2023版] 最新五年平均 出版当年[2011版] 出版当年五年平均 出版前一年[2010版] 出版后一年[2012版]

第一作者:
第一作者机构: [1]Center for Human Molecular Biology & Genetics, Institute of Laboratory Medicine, The Key Laboratory for Human Disease Gene Study of Sichuan Province, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, PR China
通讯作者:
通讯机构: [4]Laboratory of Early Developmental and Injuries, West China Institute of Woman and Children’s Health, West China Second University Hospital, Sichuan University, Chengdu, PR China [5]Key Laboratory of Birth Defects, Obstetric & Gynecologic and Pediatric Diseases (Sichuan University), Ministry of Education, PR China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43377 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号